MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Alkermes PLC

Chiusa

SettoreSettore sanitario

29.22 -0.48

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.01

Massimo

29.57

Metriche Chiave

By Trading Economics

Entrata

-124M

22M

Vendite

-123M

307M

P/E

Media del settore

14.138

39.857

EPS

0.291

Margine di Profitto

7.329

Dipendenti

1,800

EBITDA

-168M

14M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+38.08% upside

Dividendi

By Dow Jones

Utili prossimi

29 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-832M

5B

Apertura precedente

29.7

Chiusura precedente

29.22

Notizie sul Sentiment di mercato

By Acuity

50%

50%

154 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Alkermes PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 lug 2025, 21:01 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 20:50 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 20:46 UTC

Utili

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 lug 2025, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 20:36 UTC

Utili

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 lug 2025, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 lug 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 20:02 UTC

Discorsi di Mercato

Gold Higher to Close Out Week -- Market Talk

18 lug 2025, 19:14 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 lug 2025, 19:06 UTC

Discorsi di Mercato

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 lug 2025, 18:24 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 lug 2025, 18:19 UTC

Utili

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 lug 2025, 18:11 UTC

Acquisizioni, Fusioni, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 lug 2025, 18:11 UTC

Utili

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 lug 2025, 17:35 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 lug 2025, 16:29 UTC

Discorsi di Mercato

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 lug 2025, 16:28 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lug 2025, 16:22 UTC

Utili

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

18 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

18 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

18 lug 2025, 16:04 UTC

Utili

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

18 lug 2025, 15:58 UTC

Discorsi di Mercato

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 lug 2025, 15:47 UTC

Discorsi di Mercato
Utili

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Confronto tra pari

Modifica del prezzo

Alkermes PLC Previsione

Obiettivo di Prezzo

By TipRanks

38.08% in crescita

Previsioni per 12 mesi

Media 40.54 USD  38.08%

Alto 46 USD

Basso 34 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Alkermes PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

14 ratings

9

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

27.95 / 30.91Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

154 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.